NASDAQ:ACHV 17 October 2025 - 21 June 2026

Achieve Life Sciences stock exploded higher on the FDA news, reflecting growing optimism around cytisinicline’s prospects. In pre-market trading on Oct. 17, ACHV jumped about 22.7% after the company revealed it received a rare FDA Commissioner’s National Priority Voucher for cytisinicline’s vaping cessation indication investing.com. This rally propelled the shares to multi-month highs in the mid-$3 range. Earlier in the week, ACHV had already begun gaining momentum – on Oct. 15 the stock broke above its 200-day moving average and hit $3.19 marketbeat.com, a bullish technical signal. As of Thursday’s close, the stock was at $3.08, up roughly 10% over the past month and far outperforming the broader market investing.com. Year-to-date, Achieve’s performance has been volatile but positive. The stock is up markedly from its summer lows, thanks to a string of encouraging milestones. It briefly dipped in early autumn when one rating agency, Weiss Ratings, maintained a “sell” grade on ACHV marketbeat.com, reflecting cautious sentiment. However, momentum quickly recovered heading into mid-October, buoyed by regulatory progress. With the latest FDA catalyst, Achieve’s share price is now hovering near its highest levels of 2025, and trading volume has spiked as investors digest the news. The company’s market capitalization of about